Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumabValentina Guarneri, Federica Miglietta, Massimo Ferrucci et al.|npj Breast Cancer|2025Cited by 2
Basal-like HR + /HER2- breast cancers show higher tumor-infiltrating lymphocytes and immune signatures with potential therapeutic implicationsGaia Griguolo, Valentina Guarneri, Michele Bottosso et al.|npj Breast Cancer|2025Cited by 1